Abstracts tagged "Qualitative Research"

Abstract Number: 0645 • ACR Convergence 2021
Time Burden of QTc Screening for HCQ Users at a Single VA Rheumatology Clinic
Iziegbe Ehiorobo¹, Anna Montgomery² and Gabriela Schmajuk¹, ¹University of California San Francisco, San Francisco, CA, ²Department of Veterans Affairs, Tiburon, CA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication in the treatment of rheumatic diseases. New guidance from the ACR supports routine monitoring of the QT…
Abstract Number: 1755 • ACR Convergence 2021
Increasing Participation of Underrepresented Groups in Lupus Clinical Trials: Insights from Qualitative Interviews with Patients and Physicians
Saira Sheikh¹, Maria Naylor², Becky Lane², Jennifer Sacks², Janine Gaiha-Rohrbach² and Cherie Butts², ¹University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ²Biogen, Cambridge, MA
Background/Purpose: Systemic lupus erythematosus disproportionately affects Black/African American (AA) and Latino/a populations.1 Challenges to engage and include these populations in clinical trials (CTs) can be…
Abstract Number: 0799 • ACR Convergence 2021
Relationships of Rheumatology Care and Patient Experiences to Rheumatoid Arthritis Remission
Kelly O'Neill¹, Kathryne Marks², Pamela Sinicrope³, Cynthia Crowson⁴, Elena Myasoedova³ and John Davis³, ¹Rheumatoid Patient Foundation, Lutz, FL, ²Rheumatoid Patient Foundation, Boston, MA, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: Remission is a well-established optimal outcome in rheumatoid arthritis (RA) treatment, yet a minority of patients reach this goal. There is not one recognized…
Abstract Number: 1069 • ACR Convergence 2021
Supporting Patient-Centered Care in the Pediatric Rheumatology Setting: Patient, Family and Provider Experiences with OurNotes
Uptej Khalsa¹, Rajdeep Pooni², Christy Sandborg¹, Imelda Balboni¹, Karen Wayman³ and Tzielan Lee⁴, ¹Stanford University, Palo Alto, CA, ²Stanford Children's Health, Palo Alto, CA, ³Stanford Children’s Health, Palo Alto, CA, ⁴Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Health information transparency enabled by the widespread adoption of patient portals and open notes has truly transformed the way healthcare is delivered. However, broader…
Abstract Number: 1122 • ACR Convergence 2021
Patient-perceived Solutions to the Treatment Barriers in Knee Osteoarthritis: A Qualitative Study from a Diverse Patient Group Including Racial/ethnic Minorities
Jasvinder Singh, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Knee osteoarthritis (OA) has worse outcomes in racial/ethnic minorities. Yet, most of the qualitative studies include primarily Caucasian people with knee OA, with minimal…
Abstract Number: 1123 • ACR Convergence 2021
“It’s a Dance Between Managing Both [Diabetes and Osteoarthritis]”: A Qualitative Study Exploring Perspectives of Persons with Knee Osteoarthritis and Type 2 Diabetes Mellitus on the Impact of Osteoarthritis on Diabetes Management and Daily Life
Lauren King¹, Esther Waugh¹, Crystal McKay¹, Ian Stanaitis² and Gillian Hawker¹, ¹University of Toronto, Toronto, ON, Canada, ²Women's College Hospital, Toronto, ON, Canada
Background/Purpose: The links between osteoarthritis (OA) and other common chronic conditions, such as type 2 diabetes mellitus (T2DM), are increasingly being appreciated in epidemiological studies.…
Abstract Number: 1157 • ACR Convergence 2021
Patient Perspective on the Non Medical Switch of Originator to Its Biosimilar in Inflammatory Arthritis Using a Social Media Survey
David Vega Morales¹, Alejandro Garza-Alpirez² and Carlos Andrés Díaz-Garza², ¹Hospital Universitario, Garcia, Mexico, ²Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, San Pedro, Mexico
Background/Purpose: The use of biosimilars instead of its originator is a controversial subject with many implications. It is considered that a non medical switch should…
Abstract Number: 1159 • ACR Convergence 2021
Improving Healthcare Transition Implementation: Recommendations from Young Patients with Rheumatic Conditions
Courtney Wells¹, Peter Chira², Dana Guglielmo³, Stacy Ardoin⁴, Katelyn Melcher⁵, Meghan Trimble⁶ and Kristine Carandang⁷, ¹University of Wisconsin-River Falls, White Bear Lake, MN, ²Pediatric Rheumatology, University of California San Diego, Rady Children’s Hospital, San Diego, CA, ³Student, Atlanta, GA, ⁴Nationwide Children's Hospital, Columbus, OH, ⁵Patient Partner, Ankeny, IA, ⁶Patient Partner, Minneapolis, MN, ⁷Independent, San Diego, CA
Background/Purpose: Implementation of structured healthcare transition processes remains elusive for most US rheumatology clinics (Johnson et al., 2021). Although research studies have proposed models and…
Abstract Number: 1161 • ACR Convergence 2021
Patient Preferences for Hydroxychloroquine in Systemic Lupus (SLE)
Jennifer Dollinger¹, Celline Brasil¹, Marcus Wong¹, Glen Hazlewood², Ryan Dollinger¹, Wendy Singer³, Christian Pineau⁴, Evelyne Vinet⁵, Ann Clarke², Jennifer Lee¹ and Sasha Bernatsky⁴, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³McGill University Health Centre, Montréal, QC, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Although hydroxychloroquine (HCQ) has been shown to reduce SLE flares, concerns exist regarding side effects from long-term use. Very little information is available on…
Abstract Number: 1167 • ACR Convergence 2021
Rheumatoid Arthritis Patients’ Treatment Goals Relate to Disease Activity and Rheumatology Experiences
Kelly O'Neill¹, Pamela Sinicrope², Kathryne Marks³, Elena Myasoedova², Cynthia Crowson⁴ and John Davis², ¹Rheumatoid Patient Foundation, Lutz, FL, ²Mayo Clinic, Rochester, MN, ³Rheumatoid Patient Foundation, Boston, MA, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: Shared decision making and treat to target are recognized guidelines to treat Rheumatoid Arthritis (RA). We previously reported associations of shared treatment goal discussions…
Abstract Number: 1277 • ACR Convergence 2021
Patient Perspectives on Two Distinct Patterns of Type 2 SLE Symptoms
Amanda Eudy¹, Jennifer Rogers², Amy Corneli², Kevin McKenna², David Pisetsky³, Mithu Maheswaranathan², Lisa Criscione-Schreiber², Jayanth Doss¹, Rebecca Sadun¹, Kai Sun² and Megan Clowse⁴, ¹Duke University, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: The Type 1 & 2 SLE Model was developed to better characterize the signs and symptoms of SLE. Type 1 SLE consists of inflammatory…
Abstract Number: 1280 • ACR Convergence 2021
Generation of Evidence Supporting the Content Validity of SF-36, Lupus-Qol, and FACIT-Fatigue, and Newly Developed Patient-reported Outcome (PRO) Symptom Items to Address Conceptual Gaps for Use in Patient with Lupus Nephritis
Rebecca Hall¹, Nicola Williamson¹, Melissa Barclay¹, Anna Roberts¹, Adam Gater¹, Chloe Tolley¹, Helena Bradley¹, Amy Ward¹, Patricia Delong², Elizabeth Hsia³, Qing Zuraw⁴, Zahi Touma⁵, Vibeke Strand⁶ and Pamela Berry², ¹Adelphi Values Ltd, Bollington, United Kingdom, ²Janssen Global Services, LLC, Horsham, PA, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen R&D, Wayne, PA, ⁵University of Toronto, Mississauga, ON, Canada, ⁶Stanford University School of Medicine, Portola Valley, CA
Background/Purpose: Lupus nephritis (LN) is an autoimmune disease characterized by inflammation of the kidneys, a severe manifestation of systemic lupus erythematosus (SLE) that occurs in…
Abstract Number: 1130 • ACR Convergence 2020
Patient Perspectives on Biobanking and Data-linkage for Rheumatic Disease Research
Abhishikta Dey¹, Marita Cross², Tom Lynch³, Carlos El-Haddad⁴ and Lyn March⁵, ¹NSW Rheumatology Advanced Trainee, Sydney, New South Wales, Australia, ²Institute of Bone and Joint Research, University of Sydney, Sydney, Australia, ³A3BC, Sydney, New South Wales, Australia, ⁴Liverpool Hospital, Sydney, Australia, ⁵Institute of Bone and Joint Research, University of Sydney, Sydney, New South Wales, Australia
Background/Purpose: The causes of arthritis and autoimmune conditions remain unknown. A complex interplay of genetic and environmental factors is thought to underlie these diseases. Prospective…
Abstract Number: 1967 • ACR Convergence 2020
Combating Rheumatologist Burnout: Use of Protocol Driven Medication Refill by Pharmacists
Eva Rottmann¹, Jonida Cote², Swana Thomas³, Dante Grassi¹, Joseph Chronowski¹, Lisa L. Schroeder¹, David Pugliese⁴ and Eric Newman¹, ¹Geisinger Medical Center, Danville, PA, ²Geisinger Medical Center, Danvile, PA, ³Geisinger Medical Center, Wilkes-Barre, PA, ⁴Geisinger Health System, Wilkes Barre, PA
Background/Purpose: Increased electronic health record (EHR) administrative workload is a great source of physician dissatisfaction. We embedded pharmacists into our Rheumatology team in 2019. This…
Abstract Number: 1131 • ACR Convergence 2020
Patient Perspective of Helpfulness of Lupus Medications: A Qualitative Study of Medication Use Within the Type 1 and 2 SLE Model
Mithu Maheswaranathan¹, Kevin McKenna², Amy Corneli², David Pisetsky³, Megan Clowse⁴ and Amanda Eudy¹, ¹Duke University, Durham, NC, ²Duke University, Durham, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Medication management in systemic lupus erythematosus (SLE) is particularly complex given the clinical heterogeneity of symptoms and a wide range of medications used. We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].